Contraindications and Precautions for IV Reclast (Zoledronic Acid)

Absolute Contraindications

The American Academy of Family Physicians recommends that patients with hypocalcemia should not receive zoledronic acid until the hypocalcemia is corrected 1, 2
The American Academy of Family Physicians states that severe renal impairment, defined as creatinine clearance less than 35 mL/min per 1.73 m², is a contraindication for zoledronic acid 1, 2
Patients with known hypersensitivity to zoledronic acid or any components of the formulation should not receive the drug, as recommended by the American Academy of Family Physicians 1, 2

For patients with moderate renal impairment, defined as creatinine clearance 30-60 mL/min, the European Society for Medical Oncology recommends dose reduction rather than complete avoidance 3, 4
The European Society for Medical Oncology suggests that the maximum dose should be reduced to 3 mg with no change to infusion time in moderate renal impairment 3, 4

The American Society of Clinical Oncology recommends that serum creatinine should be measured before each dose 5
The American Society of Clinical Oncology suggests intermittent evaluation (every 3-6 months) for albuminuria in patients receiving chronic therapy, and discontinuation is warranted if unexplained albuminuria (>500 mg/24 hours) develops 6, 7